- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
MDS-Related Complications Impacting Patient Quality of Life
Key opinion leaders discuss how patient quality of life is impacted by MDS treatment-associated challenges.
EP: 1.Myelodysplastic Syndrome (MDS) Overview
EP: 2.Distinguishing Between Different MDS Subtypes
EP: 3.MDS-Related Complications Impacting Patient Quality of Life
EP: 4.Economic Implications of MDS Management
EP: 5.Examining Treatment Algorithms for MDS
EP: 6.Growth Factor and Stem Cell Transplant Candidacy in MDS
EP: 7.Novel Agents Contributing to Evolving MDS Therapy Strategies
EP: 8.Benefits of Oral Therapies In MDS Treatment Adherence
EP: 9.Adapting MDS Treatment Approach
EP: 10.Novel Therapy Impact on Patient Quality of Life
EP: 11.Multidisciplinary Care Driving Effective MDS Treatment
EP: 12.Payor Considerations In MDS Management
EP: 13.Navigating Insurance-Related Challenges Associated With MDS Treatment
EP: 14.Key Considerations Surrounding MDS Treatment
The discussion delves into the multifaceted impact of myelodysplastic syndromes (MDS) on patients, treatment approaches, and the challenges they pose. Highlighting the stark differences between low and high-risk MDS patients, the conversation underscores the significant anxieties and management needs for those requiring frequent transfusions. The logistical complexities of routine blood tests leading to potential transfusions profoundly affect patients' lives, posing economic burdens due to missed workdays and necessitating caregiver support.
Dr. Birhiray emphasizes the profound burden on patients, highlighting how clinicians may not always recognize the extent of these challenges. Absenteeism's real impact on employee well-being is noted, emphasizing the broader implications beyond individual patient care.
The critical consideration of treatment options between intravenous (IV) and oral therapies is discussed in the context of MDS being a lifelong condition without a cure. The discussion revolves around patient compliance and the need for more convenient treatment methods. Dr. Birhiray stresses the importance of engaging patients in shared decision-making regarding therapy options, acknowledging the significance of holistic care beyond medication in MDS management.
The conversation underscores the economic considerations, including travel for treatments in rural areas and the need for medical policy understanding among healthcare directors. Overall, the discussion stresses the need for tailored, patient-centric approaches in MDS management that encompass treatment convenience, economic impact, and the broader landscape of care.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
